Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review

Zahra Kolahchi, MohammadHossein Khanmirzaei, Ashkan Mowla

Tehran University of Medical Sciences, Tehran, Iran
Division of Stroke and Endovascular Neurosurgery, Department of Neurological Surgery, Keck School of Medicine, University of Southern California, CA, USA

ARTICLE INFO
Keywords:
COVID-19 Vaccination Thrombosis Thrombocytopenia Acute ischemic stroke Cerebral infarction

ABSTRACT
Introduction: One of the rare but potentially serious side effects of COVID-19 vaccination is arterial and venous thrombosis. Acute ischemic stroke (AIS) cases have been reported post COVID-19 vaccination. Herein, we systematically reviewed the reported cases of AIS after COVID-19 vaccination.

Method: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. We searched PubMed and Scopus until April 14, 2022 to find studies that reported AIS post COVID-19 vaccination.

Results: We found 447 articles. From those, 140 duplicates were removed. After screening and excluding irrelevant articles, 29 studies (43 patients) were identified to be included. From all cases, 22 patients (51.1%) were diagnosed with AIS associated with Vaccine-induced immune thrombocytopenia (VITT). Among AIS associated with VITT group, all received viral vector vaccines except one. The majority of cases with AIS and VITT were female (17 cases, 77.2%) and aged below 60 years (15 cases, 68%). Fourteen patients (32.5%) had additional thrombosis in other sites. Four of them (0.09%) showed concurrent CVST and ischemic stroke. Hemorrhagic transformation following AIS occurred in 7 patients (16.27%). Among 43 patients with AIS, at least 6 patients (14%) died during hospital admission.

Conclusion: AIS has been reported as a rare complication within 4 weeks post COVID-19 vaccination, particularly with viral vector vaccines. Health care providers should be familiar with this rare consequence of COVID-19 vaccination in particular in the context of VITT to make a timely diagnosis and appropriate treatment plan.

1. Introduction
The coronavirus disease-2019 (COVID-19) pandemic has posed serious challenges to the global public health, economics and social life [1–3]. Immunization of the whole population is a critical step in combating the COVID-19 pandemic. Unfortunately, adverse effects have been reported following vaccination [4,5]. Numerous COVID-19 vaccines have already been produced and released to the market, and several others are still undergoing clinical trials. The public’s adoption of vaccinations is influenced by the information about vaccine safety and side effects [6,7]. The most common side effects following COVID-19 vaccination include a local reaction at the injection site and non-specific flu-like symptoms like fever, myalgia, fatigue and headache. These symptoms may appear immediately after immunization and disappear quickly [8]. There are also reports of rare but potentially serious side effects such as arterial or venous thrombosis, Guillain-Barré syndrome (GBS), myocarditis, pericarditis, and glomerular disease [9,10]. AIS and cerebral venous sinus thrombosis (CVST) not only have been described as rare and serious neurological consequences of SARS-CoV-2 infection [11–24], but also have been outlined post COVID-19 vaccination [5,25–27]. AIS following COVID-19 vaccination has been reported in association with Vaccine-induced thrombotic thrombocytopenia (VITT) [28–30]. VITT has been previously reported with CVST post COVID-19 vaccination [30,31]. This systematic review aims to summarize reports of AIS following COVID-19 vaccination and provide insight into its pathophysiology, clinical picture and management.

2. Method
This systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Fig. 1) guideline [32]. We searched PubMed and Scopus until April 14, 2022. Details of search strategies are provided in supplementary data. The literature search was carried out separately by two reviewers to find studies that reported AIS post COVID-19 vaccination. Case reports, case series, original articles, editorial letters and short communications in English were collected. After removing duplicates, title and abstract screening was performed. The reference lists of included articles were analyzed to identify relevant studies. Collected data from articles was entered into Microsoft Excel.

3. Results and discussion

We found 447 articles after searching PubMed and Scopus until April 14, 2022 (Fig. 1). From those, 140 duplicates were removed. After excluding irrelevant articles, 29 studies (43 patients) were identified including 31 patients (72.1%) with viral vector vaccines, 8 patients (18.6%) after mRNA vaccines and 4 patients (9.3%) after whole inactivated virus vaccines.

3.1. Viral vector vaccine

Two types of viral vector vaccines including Vaxzevria (ChAdOx1 nCov-19) and Janssen COVID-19 Vaccine (Ad26.COV2-S) have been developed and administered globally [33]. We found just one report indicating AIS post Ad26.COV2-S vaccination, but ChAdOx1 nCov-19 was the most common vaccine (30 cases, 69.7%) associated with AIS. ChAdOx1 nCov-19 vaccine has about 64.1% efficacy against severe SARS-CoV-2 infection after the first dose and 70.4% after two doses [34,35]. The Oxford COVID-19 Vaccine Trial Group performed a phase 1–2 trial to assess the safety, reactogenicity, and immunogenicity of ChAdOx1 nCov-19 vaccine and documented local and systemic reactions including pain at the injection site, fever, chills, asthenia, myalgia and headache [36]. There were no serious side effects associated with the administration of ChAdOx1-S in phase 1–2 trial [36]. Since the start of the large-scale vaccination program, a few rare adverse effects that could be associated with ChAdOx1 nCov-19 have been observed. GBS and vaccine-induced thrombotic thrombocytopenia (VITT), which can be accompanied by hemorrhages, have been reported in several cases following ChAdOx1 nCov-19 injection [33]. Venous thrombosis in unusual locations such as the splanchnic venous circulation and cerebral venous sinus thrombosis (CVST) and also arterial thrombosis have been described in rare occasions [33].

Ad26.COV2-S vaccine can be effective as much as 66.9% in preventing symptomatic SARS-CoV-2 infection after 14 days after injection. Also, 76.7% and 84.5% efficacy against severe-critical COVAID-19 after 14 and 28 days following vaccination have been reported, respectively [37]. Although we found only one report of AIS post Ad26.COV2-S vaccination, previous studies have shown several cases of VITT following Ad26.COV2-S vaccination, some associated with CVST [38–40].

Table 1 illustrates reported cases of AIS following viral vector vaccination. We found 22 articles that describe 31 patients (30 with ChAdOx1 nCov-19 and 1 with Ad26.COV2-S). The majority of them (67.7%, 21 cases) had thrombocytopenia with positive anti-PF4 antibodies, indicating VITT diagnosis. From all of viral vector vaccine cases with AIS, 5 cases (16.1%) died within the hospital admission.

3.2. mRNA vaccine

The Moderna (mRNA-1273) and Pfizer-BioNTech (BNT162b2) are two types of mRNA COVID-19 vaccine with high efficacy (> 94%) [41,42]. Due to the short production time, scalability, safe administration, and potential to induce T-helper 1 (Th1) and T-helper 2 (Th2) responses, the mRNA-based vaccine technology represents a rapidly widely available vaccine candidate and provides a viable alternative to the existing vaccines till now [43]. Their side effects are usually mild and transient [41,43], however rare cases of myocarditis and pericarditis have been reported post vaccination [44]. Moreover, several cases of venous and arterial thrombosis following mRNA vaccination have been reported [45,46], some associated with VITT [47,48]. Table 2 shows reported cases of AIS post mRNA vaccine injection. Five articles including 8 patients (7 BNT162b2 and 1 mRNA-1273) were identified in our search. Two of them had thrombocytopenia, out of those, one patient was positive for anti-PF4 antibodies. One case (12.5%) died during the hospital admission.
Table 1
Summary reports of acute ischemic stroke following the COVID-19 vaccination with viral vector vaccines.

| Author(s)                      | No. of cases | Vaccine dose | Age | Gender | Past medical history/medication(s) | Time from vaccination (days) | Clinical presentation | Imaging findings | Lab findings | Treatment/outcome                     |
|--------------------------------|--------------|--------------|-----|--------|-----------------------------------|-------------------------------|------------------------|-------------------|-------------|--------------------------------------|
| ChAdOx1 nCoV-19                | 1            | First        | 43  | male   | obesity, hyperlipidemia            | 3                            | Right hemiparesis     | Left paraventricular parietal infarct | Platelets count: NL | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | antiplatelets and statins therapy/alive |
| M. A. Alammar [113]            |              |              |     |        |                                    |                              |                        |                                |             |                                      |
| T. Al-Mayhani et al. [28]      | 3            | First        | N/A | female | N/A                               | 11                           | Headache, left hemiparesis, right gaze preference and drowsiness | Thrombosis of right MCA (M1 segment) + haemorrhagic transformation | Thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | Decompressive hemicraniecytomy, IVIG, fondaparinux and plasmapheresis/dead |
| N/A                            |              | First        | 37  | female |                                    | 12                           | Diffuse headache, left visual field loss, confusion and left arm weakness | Concurrent thrombosis: left and right ICA occlusion | Thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | IVIG, methylprednisolone, plasmapheresis and fondaparinux/alive |
| N/A                            |              | First        | 43  | female |                                    | 21                           | Dysphasia              | Acute left frontal and insular infarct (MCA territory) + haemorrhagic transformation | Thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | Platelet transfusion, IVIG, and fondaparinux/alive |
| S. A. Assiri et al. [80]       | 4            | First        | 66  | male   | Cardiomyopathy, DM, HTN, dyslipidemia, IHD, prior stroke/ASA DM                | 10                           | Motor, sensory, vision, aphasia, dysphagia | Right MCA infarct | Platelets count: NL, increased level of D-dimer | rPA/alive |
| G. Berlot et al. [116]         | 1            | First        | 69  | female | HTN, hysterectomy                  | 9                            | Headache, left hemiparesis | ICA and MCA occlusion, right hemispheric infarction concurrent thrombosis descending aorta, celiac triad, inferior mesenteric artery, and left pulmonary artery | Thrombocytopenia, increased level of D-dimer, anti-PF4 reduced fibrinogen antibodies: positive | Thrombosis aspiration, intravenous dexamethasone, IVIG, argatroban, mannitol, decompressive craniotomy/alive |
| R. A. Blauenfeldt et al. [117] | 1            | First        | 60  | female | HTN and Hashimoto thyroiditis      | 9                            | Headache, left hemiparesis and eye deviation to the right | Right MCA territory infarct | Thrombocytopenia, increased level of D-dimer | Hydrocortisone, dalteparin, platelet concentrates, hemicraniecytomy/dead |
| N. Ceschia et al. [118]        | 1            | First        | 73  | female | Hypercholesterolemia, HTN, positive family history for thrombophilia | 9                            | Right PCA infarct | Right PCA infarct concurrent thrombosis: CVST, thrombosis in right medial gastrocnemius veins, pulmonary, left renal vein, right superficial femoral artery | Thrombocytopenia, increased level of D-dimer | IVIG, dexamethasone, fondaparinux and then warfarin, thromboendoarterectomy of right femoral artery | Hydrocortisone, dalteparin, platelet concentrates, hemicraniecytomy/dead |
| D. G. Corrêa et al. [119]      | 1            | First        | 64  | male   | HTN                                 | 2                            | Right superior and inferior limbs paresia | Left nucleo-capsular infarct | Platelets count: NL | ASA/alive |

(continued on next page)
### Table 1 (continued)

| Author(s) | No. of cases | Vaccine dose | Age gender | Past medical history/medication(s) | Time from vaccination (days) | Clinical presentation | Imaging findings | Lab findings | Treatment/outcome |
|-----------|--------------|--------------|------------|-----------------------------------|-----------------------------|----------------------|-----------------|--------------|------------------|
| G. Costentin et al. [111] | 1 | First * 26 female | None/ocp | headache, right hemiplegia and aphasia | 8 | Left MCA and M1 segment occlusion concurrent thrombosis: PE and portal vein thrombosis | thrombocytopenia, anti-PF4 antibodies: positive, decreased level of fibrinogen | mechanical thrombectomy: N/A |
| M. De Michele et al. [110] | 2 | First * 57 female | mild hypothyroidism, treated breast cancer | left hemiplegia, right gaze deviation, dysarthria, and left neglect | 9 | first a Right MCA infarction and then a malignant infarct due to re-occlusion of MCA Concurrent thrombosis: thrombosis of splanchic vein, pulmonary arteries | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | platelet transfusion, mechanical thrombectomy, betamethasone, decompressive craniectomy, IVIG, plasma exchange, fondaparinux/N/A |
| First * 55 female | mild hypothyroidism | 10 | transient aphasia and right hemiparesis, and then generalized seizures and coma | Right ICA and bilateral MCA infarct Concurrent thrombosis: thrombosis of portal vein, pulmonary arteries occlusion of left M1 segment of MCA, minor ischemic changes in the left basal ganglia and insula + hemorrhagic transformation | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | IVIG, dexamethasone/dead |
| J. Kenda et al. [108] | 1 | First * 51 female | hyperlipidemia | global aphasia, right sided hemiplegia and hemianopsia | 7 | MCA and ACA occlusion, ischemia on the right middle temporal gyrus, insula and putamen + hemorrhagic transformation | thrombocytopenia, high level of D-dimer, anti-PF4 antibodies: positive | rtPA, mechanical thrombectomy, IVIG, fondaparinux and then ASA/alive |
| M. Mancuso et al. [29] | 1 | First * 42 female | none | left hemiparesis | 9 | MCA and ACA occlusion, ischemia on the right middle temporal gyrus, insula and putamen + hemorrhagic transformation | thrombocytopenia, high level of D-dimer, anti-PF4 antibodies: positive | mechanical thrombectomy, intravenous dexamethasone, IVIG, fondaparinux, platelet transfusion, decompressive hemicraniectomy/alive |
| M. Scully et al. [30] | 2 | First * 39 female | none | N/A | 10 | MCA infarct | thrombocytopenia, high level of D-dimer, anti-PF4 antibodies: positive, increased level of fibrinogen | N/A/alive |
| First * 21 male | none | 10 | N/A | MCA infarct | thrombocytopenia, high level of D-dimer, anti-PF4 antibodies: positive, increased level of fibrinogen | N/A/alive |
| A. Wills et al. [120] | 1 | N/A * 42 female | smoker | left hemiplegia | 14 | Left CCA and right ICA infarct, then MCA and ACA infarcts | thrombocytopenia, anti-PF4 antibodies: positive, decreased level of fibrinogen | enoxaparin, heparin/dead |
| M. Garnier et al. [112] | 1 | N/A * 26 female | N/A | Right hemiplegia, aphasia, headache, nausea | 8 | Right MCA infarction, concurrent thrombosis: PE, portal thrombosis extending to the splenomesenteric trunk and ileal veins | thrombocytopenia, anti-PF4 antibodies: positive, decreased level of fibrinogen | thrombectomy, corticosteroids, plasmatic exchange and anticoagulant/alive |
| A. Tiede [121] | 2 | First * 61 female | N/A | Headache, dysarthria, left-sided hemiplegia, conjugated gaze palsy | 9 | Right MCA and ICA thrombosis, right MCA territory infarction + hemorrhagic transformation | thrombocytopenia, high level of D-dimer, anti-PF4 antibodies: positive | Argatroban, IVIG, dexamethasone/alive |
| First * 67 female | N/A | 8 | headache | Cortical infarctions, concurrent thrombosis: aortic arch thrombi | thrombocytopenia, high level of D-dimer, anti-PF4 antibodies: positive | Argatroban, IVIG, dexamethasone/alive |
| U. Walter et al. [122] | 1 | First * 31 smoker | N/A | acute headache, aphasia, and right hemiparesis | 8 | Left MCA thrombosis and territory infarction Concurrent thrombosis: | platelets count: NL, increased level of D-dimer, anti-PF4 antibodies: positive | rtPA, thrombectomy, ASA, danaparoid and then phenprocoumon/alive |

(continued on next page)
Table 1 (continued)

| Author(s) | No. of cases | Vaccine dose | Age | Gender | Past medical history/medication(s) | Time from vaccination (days) | Clinical presentation | Imaging findings | Lab findings | Treatment/outcome |
|-----------|---------------|--------------|-----|--------|-----------------------------------|-----------------------------|------------------------|----------------|-------------|-------------------|
| K. Y. Park et al. [31] | 1 | N/A | 69 | female | CAD, hyperlipidemia/ASA, rivaroxaban | 13 | dysarthria | small infarctions both MCA territories | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | Rivaroxaban/alive |
| M. George et al. [123] | 1 | N/A | 71 | male | N/A | 3 | Seizures | left Temporoparietal Cortex infarct | increased D-dimer | Antiplatelets, Antiepileptics/N/A |
| E. Pang et al. [124] | 1 | First | 51 | female | DM, obesity, nephrectomy | 13 | headache, Asymmetric (right >left) quadriplegia and aphasia | ICA thrombosis, left hemispheric internal watershed infarcts Concurrent thrombosis: CVST basilar thrombosis, infarction of right occipito-temporal, superior cerebellar, thalamic and internal capsula regions, pons, and mesencephalon. Concurrent thrombosis: left portal branch and right suprarenal vein, aortic arch floating thrombus | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | mechanical thrombectomy, IVIG, fondaparinux and then bivalirudin, methylprednisolone/alive |
| V. D’Agostino et al. [125] | 1 | N/A | 54 | female | Meniere's disease | 12 | Left side signs, GCS 13 | Right MCA infarction + hemorrhagic transformation Concurrent thrombosis: right internal carotid artery, CVST, right internal jugular vein, hepatic vein, and distal lower-limb vein; PE | thrombocytopenia, increased level of D-dimer | N/A/Dead |
| A. Bourguignon et al. [126] | 1 | N/A | 69 | male | DM, HTN, Obstructive Sleep Apnea, prostate cancer | 12 | Headache, confusion and left hemiplegia | Right MCA infarction + hemorrhagic transformation Concurrent thrombosis: right internal carotid artery, CVST, right internal jugular vein, hepatic vein, and distal lower-limb vein; PE | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | Fondaparinux, IVIG, rivaroxaban, plasma exchange/alive |
| Ad26.COV2-S A. Charidimou et al. [127] | 1 | N/A | 37 | female | Migraine/ocp | 10 | headache, left hemiparesis, hemineglect and right gaze deviation | occlusion of Right ICA, MI segment of right MCA and ACA, acute right MCA infarct + hemorrhagic transformation. Concurrent thrombosis: left brachial vein and bilateral cephalic vein, right common femoral vein | thrombocytopenia, increased level of D-dimer, anti-PF4 antibodies: positive | mechanical thrombectomy, intravenous dexamethasone, IVIG, argatroban, decompressive hemicyanectomy/N/A |

NL: normal; N/A: not available; anti-PF4 antibody; anti-platelet factor 4 antibody; IVIG: intravenous immunoglobulin; CVST: cerebral venous sinus thrombosis; MCA: middle cerebral artery; ICA: internal carotid artery; DM: diabetes mellitus; HTN: hypertension; IHD: ischemic heart disease; CAD: coronary artery disease; rtPA: recombinant tissue plasminogen activator; ASA: acetylsalicylic acid (aspirin); PCA: posterior cerebral artery; PE: Pulmonary Thrombosis.

* VITT Case.
| Author(s) | No. of cases | Vaccine dose | Age | Gender | Past medical history/medication(s) | Time from vaccination (days) | Clinical presentation | Imaging findings | Lab findings | Treatment/Outcome |
|-----------|--------------|--------------|-----|--------|-----------------------------------|----------------------------|----------------------|-------------------|-------------|----------------|------------------|
| BNT 162b2 | 4            | First        | 59  | male   | HTN, DM, dyslipidemia, smoker/clopidogrel | 12                         | Sensory, Ataxia, Vertigo affection, Aphasia, dysphagia, dysarthria | PICA infarct | Platelets count: NL, increased level of D-dimer | ASA/alive |
| S. A. Assiri et al. [80] |             | Second       | 59  | male   | Dyslipidemia, hypercholesterolemia, smoker/ASA | 23                         | Motor, Sensory, dysphagia, dysarthria | Right MCA thrombosis and infarction | Platelets count: NL, increased level of D-dimer | Thrombectomy/alive |
|          |              | Second       | 80  | female | Peripheral vascular neuropathy, dyslipidemia/ warfarin | 7                         | Motor, Sensory, Vision, Aphasia and dysphagia, dysarthria | Left MCA infarction, Left Internal Carotid Artery occlusion | Platelets count: NL, increased level of D-dimer | Thrombectomy/alive |
| G. Famularo [81] | 1            | Second       | 87  | female | Ischemic heart disease, HTN, and hyperlipidemia/ ASA | 6                         | Motor, Sensory, Aphasia and dysphagia dysarthria, right gaze deviation, and complete left hemiplegia | Left MCA thrombosis and infarction | Platelets count: NL, increased level of D-dimer | Thrombectomy/alive |
| R. Giovane et al. [128] | 1            | First        | 62  | male   | HTN, DM, hyperlipidemia, ESRD, | 1                         | Left facial paralysis, dysarthria, slurred speech, anisocoria, left lower limb hemiballismus, left upper limb paralysis, horizontal nystagmus | Right MCA occlusion | Platelets count: NL | Clopidogrel/alive |
| K. Yoshida et al. [129] | 1            | First        | 83  | female | AF/rivaroxaban | 3 (for both doses) | First stroke: right hemiplegia and motor aphasia, second stroke: left hemiplegia and left hemispatial neglect | PICA infarct | Platelets count: NL, increased level of D-dimer | First stroke: rtPA, mechanical thrombectomy, edoxaban, second stroke: mechanical thrombectomy/N/A |
| mRNA-1273 | 1            | First        | * 70| male   | AF, COPD, HTN, Pancreatic cancer/ rivaroxaban | 7                         | Left side weakness | Scattered infarcts at the right thalamus, parietal cortex, medial temporal, parietal-occipital lobe, left centrum semiovale and posterior cerebral artery territory | Thrombocytopenia, increased level of D-dimer, decreased level of fibrinogen, anti-PF4 antibodies: positive | Intravenous dexamethasone, IVIG, plasma exchange/dead |

NL: normal; N/A: not available; anti-PF4 antibody: anti-platelet factor 4 antibody; IVIg: intravenous immunoglobulin; CVST: cerebral venous sinus thrombosis; MCA: middle cerebral artery; ICA: internal carotid artery; DM: diabetes mellitus; HTN: hypertension; IHD: ischemic heart disease; CAD: coronary artery disease; rtPA: recombinant tissue plasminogen activator; ASA: acetylsalicylic acid (aspirin); PICA: posterior inferior cerebellar artery; COPD: chronic obstructive pulmonary disease; AF: atrial fibrillation; ESRD: end-stage renal disease.

* VITT Case.
### Table 3

| Author(s) | No. of vaccine cases | Clinical presentation | Imaging findings | Lab findings | Treatment/ outcome |
|-----------|----------------------|-----------------------|-----------------|-------------|-------------------|
| **BIBP (Sinopharm)** | 1 First | male | HTN, DM, dyslipidemia, headaches, left hemiplegia, left facial paralysis, left hemibody hypotonia, impaired consciousness | Phlebectasia count: ASA, Clopidogrel/ alive | ASA, Clopidogrel/ alive |
| **Sinovac** | 3 First | male | CAD, DM, HTN, ischemic stroke | PHU: DVT, HTN, ischemic stroke | Clopidogrel/ alive |
| **Sinovac** | 3 First | male | HTN, hypercholesterolemia, ischemic stroke | HTN, hypercholesterolemia, ex-smoker | Clopidogrel/ alive |
| **Sinovac** | 2 First | male | HTN, DM, HTN, ischemic stroke | HTN, hypercholesterolemia, ex-smoker | Clopidogrel/ alive |
| **Sinovac** | 1 First | male | HTN, hypercholesterolemia, ischemic stroke | HTN, hypercholesterolemia, ex-smoker | Clopidogrel/ alive |

**Summary reports of acute ischemic stroke following the COVID-19 vaccination with whole inactivated virus vaccines.**

| Author(s) | No. of vaccine cases | Clinical presentation | Imaging findings | Lab findings | Treatment/ outcome |
|-----------|----------------------|-----------------------|-----------------|-------------|-------------------|
| **BIBP (Sinopharm)** | 1 First | male | HTN, DM, dyslipidemia, headaches, left hemiplegia, left facial paralysis, left hemibody hypotonia, impaired consciousness | Phlebectasia count: ASA, Clopidogrel/ alive | ASA, Clopidogrel/ alive |
| **Sinovac** | 3 First | male | CAD, DM, HTN, ischemic stroke | PHU: DVT, HTN, ischemic stroke | Clopidogrel/ alive |
| **Sinovac** | 3 First | male | HTN, hypercholesterolemia, ischemic stroke | HTN, hypercholesterolemia, ex-smoker | Clopidogrel/ alive |
| **Sinovac** | 2 First | male | HTN, DM, HTN, ischemic stroke | HTN, hypercholesterolemia, ex-smoker | Clopidogrel/ alive |
| **Sinovac** | 1 First | male | HTN, hypercholesterolemia, ischemic stroke | HTN, hypercholesterolemia, ex-smoker | Clopidogrel/ alive |

**3.3. Whole inactivated virus vaccine**

CoronaVac (Sinovac) and BBIBP-CorV (Sinopharm), as whole inactivated virus vaccines, have been used widely around the world [49,50]. Multiple clinical trials have been conducted to evaluate CoronaVac and BBIBP-CorV efficacies but diverse results have been reported, probably due to different trial designs [51–54]. World health organization (WHO) indicates that CoronaVac has 51% efficacy against symptomatic SARS-CoV-2 infection and 100% efficacy against severe disease and hospitalization [55]. Moreover, efficacies of BBIBP-CorV against symptomatic infection and hospitalization were both 79%, according to WHO [56]. Although common side effects of these two vaccines are mild to moderate [57,58], there are rare cases of thrombotic events [59–62]. As presented in Table 3, we found 2 articles including 4 patients (3 CoronaVac and 1 BBIBP-CorV) with AIS after inactivated virus vaccine administration. None of them had thrombocytopenia, increased D-dimer or positive for anti-PF4 antibodies. No mortality was reported during the hospital course.

**3.4. Background and clinical picture of reported cases of ischemic stroke**

From all cases, 22 patients (51.1%) had VITT. Except for one case vaccinated with mRNA-1273, all of them had received viral vector vaccines. Although there was not much difference between the number of male and female patients from all included studies (44% male and 56% female), the majority of cases with possible or definite VITT diagnosis were female (17 cases, 77.2%). Sixty-eight percent (15 cases) of the VITT cases are aged below 60 years. These findings are consistent with the previous studies that reported the risk of VITT appears to be greater in younger females under 60 [63,64].

The most common cardiovascular risk factors were hypertension (16 cases, 37.2%) and hyperlipidemia (11 cases, 25.5%). Two of the VITT cases who received viral vector vaccines have a history of oral contraceptive use. Interestingly, 9 patients (21%) who were taking anti-platelet or anticoagulants were among AIS patients (5 anti-platelets, 3 anticoagulants, 1 taking both). Neurological symptoms occurred suddenly within few hours to 23 days after vaccine administration. The most common symptoms were as follows [65]: hemiplegia or hemispheric (26 cases, 60.4%), dysphasia (13 cases, 30.2%), dysarthria (12 cases, 28%) and headache (13 cases, 30.2%). Among 43 patients with AIS, at least 6 patients (14%) died during hospital admission.

Fourteen patients (32.5%) had additional thrombosis in other sites. Four of them (0.09%) showed concurrent CVST and ischemic stroke. CVST, portal vein thrombosis, pulmonary embolism, and thrombosis of jugular vein, hepatic vein, iliac veins, ophthalmic vein, medial gastrocnemius veins, renal vein, superficial femoral artery, carotid bulb, aortic arch, descending aorta, celiac triad, inferior mesenteric artery and splanchic vein were reported. All the patients with thrombosis in other sites were vaccinated with viral vector vaccines.

Hemorrhagic transformation following AIS occurred in 7 patients (16.27%).

**3.5. Pathophysiology**

The pathophysiology of VITT has not been totally understood yet. VITT, in terms of clinical manifestations, is very similar to autoimmune heparin-induced thrombocytopenia (HIT). HIT is an immune-mediated disorder induced by immunoglobulin G (IgG) antibodies against platelet factor 4 (PF4) complexed with heparin. This combination subsequently attaches to platelet FcRIIA receptors, activating platelets and causing platelet microparticle production [66]. These microparticles induce thrombocytopenia by generating blood clots and triggering a prothrombotic cascade, that lowers platelet count. Furthermore, the reticuloendothelial system, especially the spleen, eliminates antibody-coated platelets, aggravating thrombocytopenia [8,66–68]. It has also
been shown that certain individuals with clinical symptoms and biochemical markers suggestive of HIT surprisingly have not been exposed to heparin earlier. Antibodies in these individuals' sera aggressively activate platelets even in the lack of heparin. The majority of the reported spontaneous HIT cases had previously undergone orthopedic surgery (released glycosaminoglycans or RNA from knee cartilage due to tourniquet-related cell injury) or had infections (microorganism exposure) [69]. High level of anti-PF4-polyanion antibodies, as a platelet activator, is a common finding in both VITT and HIT [63]. However, the presence of these antibodies is neither a guarantee nor a prediction of VITT. Six individuals with anti-PF4-polyanion antibodies were detected in a Norwegian trial of 492 health care professionals who got one dose of ChAdOx1 nCov-19 vaccine, though these antibodies did not exhibit platelet-activating capabilities, and VITT did not occur in any of them [70]. Furthermore, anti-PF4-polyanion antibodies have not been found in suspected patients of VITT in another study [71]. Thus, it is likely that VITT pathogenesis is mediated by a number of distinct pathways.

Various possible pathways have been suggested for VITT involving platelets and PF4 thus far [72]. It's worth noting that the etiology of VITT may not be the same in every case. Thus, diverse processes should be thoroughly analyzed and investigated. One theory proposes that platelets interact directly with SARS-CoV-2 spike proteins generated after immunization. Spike proteins might have been overexpressed and released into the circulation in rare cases, interacting with platelets and causing platelet activation, PF4 release, and anti-PF4 antibody production, ultimately leading to thrombosis and thrombocytopenia [73].

Interactions between PF4 and particular COVID-19 vaccine components are another mechanism that has been suggested. Negatively charged double-stranded DNA and single-stranded mRNA can create extremely immunogenic complexes with PF4 just like heparin [73,74]. Due to microtrauma and micro bleeding at the injection site, double-stranded DNA carried by adenoviral vector-based COVID-19 vaccines, like ChAdOx1 nCov-19, can directly interact with PF4, leading to the generation of anti-PF4-polyanion antibodies which can stimulate platelets and end up causing thrombosis and thrombocytopenia [72]. A similar mechanism is probable for mRNA vaccines; however, due to changes that reduce pathogen-associated molecular pattern sensing mechanisms, such as replacement of uridine with N1-methyl-pseudouridine (m1Ψ) [75], the immunogenic risk might be lowered leading to reduced rates of VITT seen with mRNA vaccines.

Patients with SARS-CoV-2 infection experience an elevated risk of thrombotic events such as AIS, due to severe inflammation reaction and subsequent hypercoagulable state [76]. Although the exact mechanism of AIS following COVID-19 vaccination is unknown, there is a chance that it is associated with COVID-19 vaccine-induced inflammation, similar to what has been shown with SARS-CoV-2 viral infection, leading to disseminated intravascular coagulation (DIC) and vascular endothelial dysfunction which eventually might induce large-vessel stroke [77–81]. This mechanism might play a major role particularly in patients with atherosclerotic lesions [81].

3.6. Evaluation and management

During the pandemic era, practitioners should ask AIS patients about history of COVID-19 vaccinations, within the last 1 month prior to the incident. In the case of positive vaccination history, in particular with viral vector vaccines, VITT evaluation is needed. The following items should be evaluated [72]:

- Complete blood cell count including platelet count
- Prothrombin time (PT)/activated partial thromboplastin time (APTT)
- D-dimer test
- Fibrinogen test
- PF4-heparin enzyme-linked immunosorbent assay (ELISA)

Platelet count below 150 × 10^9/L [82], abnormal PT or APTT [83], significant elevation of D-dimer [83,84], low levels of fibrinogen and positive anti-PF4 antibodies [82–85] suggest VITT diagnosis.

Patients with possible or definite VITT should undergo imaging to find thrombosis in other probable sites, in particular dural sinuses and splanchnic veins [63,83]. It is suggested to admit the patients to the hospital and start non-heparin anticoagulants in case thrombosis is detected. Transfusions of platelets must be avoided [64,82,84]. Similar to the management of autoimmune HIT, administration of standard heparin or low-molecular weight heparin should be avoided. Alternative anticoagulants such as fondaparinux, danaparoid, argatroban, bivalirudin, rivaroxaban or apixaban can be used [86]. High-dose intravenous immune globulin (IVIG) treatment has been demonstrated to suppress antibody-mediated platelet activation, resulting in lower hypercoagulability and a fast rise in platelet count, and has been considered part of VITT therapy [87,88]. Plasma exchange is also recommended as a treatment option for people with refractory VITT. Anti-PF4 antibodies and increased inflammatory cytokines are removed by plasma exchange [89].

Patients who develop arterial or venous thrombosis and thrombocytopenia following receiving the ChAdOx1 nCov-19 vaccine s, should be advised not get a second dose [71,85,90].

Management of AIS associated with VITT or any kind of thrombocytopenia has not been well studied. Patients with substantial thrombocytopenia (≤100 × 10^9/L) have been generally excluded from AIS treatment with intravenous tissue-type plasminogen activator (IV tPA) clinical studies since it has been considered a relative contraindication [91]. IV tPA is the sole FDA-approved pharmacological therapy for AIS and its safety and efficacy have been studied in various settings [92–104]. Previous studies reported that the risk of symptomatic intracerebral hemorrhage (sICH) might be higher in AIS patients with severe thrombocytopenia who were treated with IV tPA, compared to those without thrombocytopenia [105,106]. Acute reperfusion therapy must be delivered to the AIS stroke patients as soon as possible and without any potential delays if there is no contraindication [107]. It's critical to cautiously use anticoagulants in AIS patients given the risk of hemorrhagic transformation, in case anticoagulant therapy is required for treatment of venous or arterial thrombosis. Hemorrhagic conversion of AIS might be fatal in individuals with low platelets and anti-coagulation, particularly when platelet transfusion is not an option [108]. Mechanical thrombectomy with the current technology has been shown to significantly increase the recanalization rate and improve clinical outcomes in AIS with intracranial large vessel occlusion (LVO) [109]. Safety of this treatment has been studied in small case series of AIS patients with thrombocytopenia. Seven cases of AIS with LVO who have thrombocytopenia underwent mechanical thrombectomy successfully and safely among our studied patients, 6 of them did not receive IV tPA prior to thrombectomy [29,108,110–112]. Cascio Rizzo et al. also indicated that despite that re-occlusion after revascularization may happen due to the hypercoagulative state, mechanical thrombectomy is a feasible and safe treatment in patients with VITT and AIS [113]. It is suggested not to use intravenous heparin throughout the thrombectomy procedure in these patients [108].

4. Conclusion

The association between AIS and prior COVID-19 vaccination is still unclear, particularly in the absence of VITT. A group of the patients studied in this systematic review have established cardiovascular risk factors and well-known underlying mechanisms such as atrial fibrillation and it is not clear if COVID-19 had any role in the development of AIS.

We suggest that health care providers taking care of stroke patients
inquire about history of COVID-19 vaccination, particularly within 1 month prior to the incident, order the appropriate blood tests and brain imaging and apply the treatment algorithm outlined in Fig. 2.

Of note, the benefits of COVID-19 vaccination remarkably outweigh the very small risk of AIS, CVST and other thrombotic events. Thus, the public must be reassured that vaccination is the most effective strategy to stop COVID-19 pandemic.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declarations of interest

The authors report no relevant conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jns.2022.120327.

References

[1] N. Rezaei, S. Ashkevarian, M.K. Fathi, S. Hanaei, Z. Kolahchi, S.S. Ladi Seyedian, et al., Introduction on coronavirus disease (COVID-19) pandemic: the global challenge, Adv. Exp. Med. Biol. 1318 (2021) 1–22.
[2] Z. Kolahchi, M. De Domenico, L.Q. Uddin, V. Cauda, I. Grossmann, L. Lacasa, et al., COVID-19 and its global economic impact, Adv. Exp. Med. Biol. 1318 (2021) 825–837.
[3] A. Mowla, Stroke care during the COVID-19 pandemic; a global challenge, Iran J. Med. Sci. 45 (5) (2020) 323–324.
[4] N.G. Kounis, I. Koniari, C. de Gregorio, D. Velissaris, K. Petalas, A. Brinia, et al., Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations, Vaccines (Basel) 9 (3) (2021).
[5] M. Sharifian-Dorche, M. Bahmanyar, A. Sharifian-Dorche, P. Mohammadi, M. Nomovi, A. Mowla, Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review, J. Neurol. Sci. 428 (2021), 117607.
[6] S. Kreps, S. Prasad, J.S. Brownstein, Y. Hswen, B.T. Garibaldi, B. Zhang, et al., Factors associated with US adults’ likelihood of accepting COVID-19 vaccination, JAMA Netw. Open 3 (10) (2020). e2025594.
[7] K. Pogue, J.L. Jensen, C.K. Stancil, D.G. Ferguson, S.J. Hughes, E.J. Mello, et al., Influences on attitudes regarding potential COVID-19 vaccination in the United States, Vaccines (Basel), 8 (4) (2020).
[8] A.F. Hernández, D. Calina, K. Pousas, A.O. Docoa, A.M. Tsatsakis, Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol. Rep. 8 (2021) 871–879.
[9] H.A. Mushag, A. Khedr, T. Koritala, B.N. Bartlett, N.K. Jain, S.A. Khan, A review of adverse effects of COVID-19 vaccines, Inflz Med. 20 (1) (2022) 1–15.
[10] M. Pourssadeghpard, M. Sharifian-Dorche, A. Nemati, A. Mowla, Simultaneous encephalitis and neuroretinitis after COVID-19 in a young adult: a case report, J. Neurol. Res. 11 (5) (2021) 102–107.
[11] F. Jabbour, A.A. Dmytryev, A. Swiet, M. Pirotin, K. Bebekis, N. Sourour, et al., Characteristics of a COVID-19 cohort with large vessel occlusion: a multicenter international study, Neurorugery. 90 (6) (2022) 725–733.
[12] A.A. Dmytryev, M. Dibas, K. Phan, A. Efendiaze, J. Ospel, C. Schirmer, et al., Acute ischemic stroke associated with SARS-CoV-2 infection in North America, J. Neurol. Neurosurg. Psychiatry 93 (4) (2022) 360–368.
A. Wills, G. Swallow, M.A. Kirkman, K. Rajan, G. Subramanian, Arterial and venous thrombotic stroke after ChAdOx1 nCoV-19 vaccine, Clin. Med. (Lond). 22 (2) (2022) 184-186.

A. Tiede, U.J. Sachs, A. Czwalinna, S. Werwitzke, R. Bikker, J.K. Krauss, et al., Prothrombotic immune thrombocytopenia after COVID-19 vaccination, Blood. 138 (4) (2021) 350-353.

U. Walter, M. Fuchs, A. Grossmann, M. Walter, T. Thiele, A. Storch, et al., Adenovirus-vectored COVID-19 vaccine-induced immune thrombosis of carotid artery: a case report, Neurology. 97 (15) (2021) 716-719.

M. George, N. Baby, A. Azad, A. Rajan, S.K. Radhakrishnan, Neurological disorders seen during second wave of SARS-CoV-2 pandemic from two tertiary care centers in central and southern Kerala, Ann. Indian Acad. Neurol. 24 (6) (2021) 917-926.

E. Pang, S. Ghosh, T. Chemmanam, C. Grove, T. Phillips, Cerebral arterial and venous thrombosis due to COVID-19 vaccine-induced immune thrombotic thrombocytopenia, BMJ Case Rep. 15 (1) (2022).

V. D’Agostino, F. Caranci, A. Negro, V. Piscitelli, B. Tuccillo, F. Fasano, et al., A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration, J Pers Med. 11 (4) (2021).

A. Bourguignon, D.M. Arnold, T.E. Warkentin, J.W. Smith, T. Pannu, J.M. Shrum, et al., Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia, N. Engl. J. Med. 385 (8) (2021) 720-728.

A. Charidimou, S. Samudrala, A.M. Cervantes-Arslanian, J.M. Sloan, H. H. Duenbrock, A. Daneshmand, Vaccine-induced immune thrombotic thrombocytopenia with concurrent arterial and venous thrombi following Ad26. COV2.S vaccination, J. Stroke Cerebrovasc. Dis. 30 (12) (2021), 106113.

R. Giovane, J. Campbell, Bilateral thalamic stroke: a case of COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) or a coincidence due to underlying risk factors? Cureus. 13 (10) (2021), e18977.

K. Yoshida, K. Tanaka, Y. Suto, H. Fukuda, Repeated cardioembolic stroke after COVID-19 mRNA vaccination: a case report, J. Stroke Cerebrovasc. Dis. 31 (2) (2022) 106233.